CoChat

Delgocitinib: First Approval

Dhillon, Sohita · 2020 · Drugs

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Delgocitinib, a janus kinase (JAK) inhibitor, is being developed by Japan Tobacco for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions. The JAK family of tyrosine kinases plays an important role in mediating the biological effects of several inflammatory cytokines, e.g. IL-4, IL-13 and IL-31, which are elevated in patients with atopic dermatitis. Delgocitinib inhibits all members of the JAK family [JAK1, JAK2, JAK3 and tyrosine kinase 2]. Topical delgocitinib (Corectim®) is approved in Japan for the treatment of atopic dermatitis. This article summarizes the milestones in the development of delgocitinib leading to this first approval for the treatment of adults with atopic dermatitis. Clinical development of the topical formulation is also underway for alopecia areata, chronic hand eczema, discoid lupus erythematosus, inverse psoriasis and atopic dermatitis in several countries worldwide. Clinical development of an oral formulation of delgocitinib is also underway in Japan for the treatment of autoimmune disorders and hypersensitivity.

Overview

Integrity signals

Registry

Crossref · 10.1007/s40265-020-01291-2

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 14 references

Cited by

See all 137

Metadata

Authors
Dhillon, S.
Affiliations
Springer Nature (New Zealand) (NZ)
Corresponding author
Dhillon, Sohita
Venue
Drugs
Published
2020-03-12
Volume
80
Issue
6
Pages
609-615
ISSN
  • 0012-6667 (ISSN-L)
  • 1179-1950
OpenAlex
W3010985734
Cited by
126
References
14
Citations by year
2026: 17 · 2025: 14 · 2024: 18 · 2023: 20 · 2022: 26 · 2021: 25 · 2020: 6
FWCI
14.43
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
  • Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
Keywords
delgocitinib, JAK inhibitors, atopic dermatitis, topical formulation, drug approval, alopecia areata, chronic hand eczema, discoid lupus erythematosus, inverse psoriasis, autoimmune disease, hypersensitivity, IL-4, IL-13, IL-31, inflammatory cytokines, oral dosage forms
MeSH terms
Janus Kinase Inhibitors, Animals, Autoimmune Diseases, Humans, Hypersensitivity, Molecular Conformation, Pyrroles, Drug Approval, Janus Kinases

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Delgocitinib: First Approval. https://app.cochat.ai/papers/10.1007/s40265-020-01291-2
The paper
Dhillon, S. (2020). Delgocitinib: First Approval. Drugs. https://doi.org/10.1007/s40265-020-01291-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.